Larvol Delta - BitNile-Holdings-Announces-That-Alzamend-Neuro-Receives-FDA-Study-May-Proceed-Letter-for-Phase-IIIA-Clinical-Trial-Under-Its-Investigational-New-Drug-Application-for-an-Immunotherapy-Vaccine-ALZN002-to-Treat-Alzheimers-Disease

ALZN002 - Alzamend Neuro

https://www.businesswire.com/news/home/20221101005692/en/BitNile-Holdings-Announces-That-Alzamend-Neuro-Receives-FDA-%E2%80%9CStudy-May-Proceed%E2%80%9D-Letter-for-Phase-IIIA-Clinical-Trial-Under-Its-Investigational-New-Drug-Application-for-an-Immunotherapy-Vaccine-ALZN002-to-Treat-Alzheimer%E2%80%99s-Disease

Nov 1, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next